EMVO has been working to manage the implications of Brexit (the UK’s departure
from the EU Internal Market rules) for the EMVS and its users. This was undertaken in
close collaboration with concerned authorities and stakeholders, including the
European Commission, as well as the most impacted National Medicines Verification
Organisations (NMVOs).

Although the final Brexit negotiations continue, EMVO is working to ensure that as
from 1 January 2021 the operation of the EMVS is adapted to the EU-UK Withdrawal
Agreement and Northern Ireland Protocol (included as an Annex thereto) that makes
certain provisions of EU law applicable “to and in the United Kingdom in respect of
Northern Ireland”.

For more information, click here.